Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada

Detalles Bibliográficos
Autores principales: Cameron, Jodi, Forgie, Jennifer, Ring, Alicia, Santucci, Stephanie, Rizk, Caroline, Pham, Hoang, O’Quinn, John, Yang, William H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Meeting Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304125/
http://dx.doi.org/10.1186/1710-1492-10-S2-A5
_version_ 1782354037523349504
author Cameron, Jodi
Forgie, Jennifer
Ring, Alicia
Santucci, Stephanie
Rizk, Caroline
Pham, Hoang
O’Quinn, John
Yang, William H
author_facet Cameron, Jodi
Forgie, Jennifer
Ring, Alicia
Santucci, Stephanie
Rizk, Caroline
Pham, Hoang
O’Quinn, John
Yang, William H
author_sort Cameron, Jodi
collection PubMed
description
format Online
Article
Text
id pubmed-4304125
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43041252015-02-12 Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada Cameron, Jodi Forgie, Jennifer Ring, Alicia Santucci, Stephanie Rizk, Caroline Pham, Hoang O’Quinn, John Yang, William H Allergy Asthma Clin Immunol Meeting Abstract BioMed Central 2014-12-18 /pmc/articles/PMC4304125/ http://dx.doi.org/10.1186/1710-1492-10-S2-A5 Text en Copyright © 2014 Cameron et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Meeting Abstract
Cameron, Jodi
Forgie, Jennifer
Ring, Alicia
Santucci, Stephanie
Rizk, Caroline
Pham, Hoang
O’Quinn, John
Yang, William H
Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
title Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
title_full Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
title_fullStr Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
title_full_unstemmed Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
title_short Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
title_sort xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in canada
topic Meeting Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304125/
http://dx.doi.org/10.1186/1710-1492-10-S2-A5
work_keys_str_mv AT cameronjodi xolairomalizumabenrollmentinatertiarycareallergyandasthmaclinicincanada
AT forgiejennifer xolairomalizumabenrollmentinatertiarycareallergyandasthmaclinicincanada
AT ringalicia xolairomalizumabenrollmentinatertiarycareallergyandasthmaclinicincanada
AT santuccistephanie xolairomalizumabenrollmentinatertiarycareallergyandasthmaclinicincanada
AT rizkcaroline xolairomalizumabenrollmentinatertiarycareallergyandasthmaclinicincanada
AT phamhoang xolairomalizumabenrollmentinatertiarycareallergyandasthmaclinicincanada
AT oquinnjohn xolairomalizumabenrollmentinatertiarycareallergyandasthmaclinicincanada
AT yangwilliamh xolairomalizumabenrollmentinatertiarycareallergyandasthmaclinicincanada

Ejemplares similares